# Nifedipine

Drug · id `cardio:nifedipine` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Nifedipine extended-release tablets

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Nifedipine is a calcium channel blocker, of the dihydropyridine type. The US label read is for nifedipine extended-release tablets and lists two uses: the management of vasospastic angina, and the management of chronic stable angina without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers or organic nitrates, or who cannot tolerate those agents. No brand-name nifedipine label was found in openFDA, so this page rests on a generic manufacturer's label.

## Technical summary

RxNorm ingredient 7417; UNII I9ZF7L6G2L. MeSH descriptor D009543 is Nifedipine. Class: Dihydropyridine Calcium Channel Blocker (FDA established pharmacologic class, RxClass). The label read is the nifedipine extended-release tablets, Upsher-Smith Laboratories, LLC label, effective 2026-01-19 in openFDA (application ANDA203126). Other nifedipine labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of nifedipine extended-release tablets lists an indication: vasospastic angina, chronic stable angina

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of nifedipine extended-release tablets, in the Upsher-Smith Laboratories, LLC version dated 2026-01-19 in openFDA, lists the medicine for the management of vasospastic angina, and for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers or organic nitrates, or who cannot tolerate those agents.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for nifedipine extended-release tablets, Upsher-Smith Laboratories, LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 3bf4282f-b063-4d35-8ef0-6f48b98e9deb (manufacturer Upsher-Smith Laboratories, LLC, application ANDA203126), returned on 2026-11-09. The label text is dated 2026-01-19 (effective\_time). Other openFDA records of nifedipine labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%223bf4282f-b063-4d35-8ef0-6f48b98e9deb%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-11-09T13:17:34Z. Source state: Current. Version fingerprint: c069ea3c1e7516d4e5f12ff730186c2bc09b702825b261ac8c2355a7f2758fdf.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for nifedipine extended-release tablets, Upsher-Smith Laboratories, LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 3bf4282f-b063-4d35-8ef0-6f48b98e9deb (manufacturer Upsher-Smith Laboratories, LLC, application ANDA203126), returned on 2026-11-09. The label text is dated 2026-01-19 (effective\_time). Other openFDA records of nifedipine labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%223bf4282f-b063-4d35-8ef0-6f48b98e9deb%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:34Z. Source state: Current. Version fingerprint: c069ea3c1e7516d4e5f12ff730186c2bc09b702825b261ac8c2355a7f2758fdf.
     How it applies: Effective date of the label text read, 20260119.

## Connected pages

- Nifedipine is a dihydropyridine calcium channel blocker (FDA established pharmacologic class in RxClass): Calcium channel blockers (`cardio:calcium-channel-blockers`)
- FDA label lists the management of chronic stable angina without evidence of vasospasm, in patients who remain symptomatic on beta blockers or organic nitrates or cannot tolerate them, as an indication: Stable angina (`cardio:stable-angina`) [a claim, not a settled fact; see claim `cardio:claim-fda-nifedipine-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 4 registry products
- 9 registry trials

## Provenance

Content hash: bb9b665dc477357852bb7e7137490499e0a32d6b236c06984cd2b31afcac7667
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
